Alba Therapeutics Corp. has made several promotions. Linda Arterburn, Ph.D., has been promoted to vice president of preclinical development and program management. Francisco Leon, M.D., Ph.D., has been promoted to vice president, clinical development and medical affairs. Roberto Allen has been promoted to vice president, legal affairs and intellectual property. Mark Ginski, Ph.D., has been promoted to senior director of product and analytical development and Kate Huber has been promoted to director of clinical operations.
   
Prior to joining the company, Dr. Arterburn was executive director of discovery research at Market Biosciences where she initiated an inflammation research program and was lead inventor on two patents involving novel anti-inflammatory lipids. Previously she led clinical research and scientific affairs at Market Biosciences. Dr. Arterburn also spent seven years at W.R. Grace & Co., where she led an in vitro toxicology research program, and then served as manager of technology and planning.
   
Dr. Leon is an immunologist with training in basic and clinical immunology and a clinical development in the field of mucosal immunology. Prior to joining the company, Dr. Leon was a director of clinical development, inflammatory and respiratory diseases at MedImmune, where he worked on asthma and mucosal vaccination. He was a director of clinical discovery, oncology / immunology at Bristol-Myers Squibb, where he worked on Crohn’s disease, rheumatoid arthritis, and transplantation.
   
Prior to joining the company, Mr. Allen was president of Respire Medical, Inc., a respiratory and home health care provider serving the Mid-Atlantic region. He was also counsel at Kollman & Saucier, P.A., where he practiced general corporate and labor and employment law. Previously, he was a senior associate in the business department at Saul Ewing LLP.
   
Dr. Ginski’s has experience with lead candidate selection, preformulation and formulation development, development, transfer and validation of analytical and bioanalytical methods, and packaging, labeling and distribution of clinical trial supplies. Prior to joining the company, Dr. Ginski served as associate director of preformulation sciences at Shire, where he played an integral role in developing and implementing Shire’s Proscreen and Optiscreen programs designed to facilitate lead candidate selection and product development. Additionally, he worked at Guilford Pharmaceuticals, where he was responsible for leading exploratory pharmaceutics and CMC programs for various development programs. He has published numerous R&D articles and is an inventor for numerous global patents.
   
Ms. Huber has more than 25 years of experience in the health care industry and has been involved in all aspects of the conduct of Phase I – III clinical trials. She has worked in managing complex projects in the areas of celiac disease, oncology, CNS, vaccines, and diagnostics for HIV, HbsAg, and tuberculosis. Ms. Huber joins the company from Nabi Biopharmaceutical and Guilford Pharmaceuticals, where she had increasing responsibilities in the vaccine, oncology and CNS arenas. She has extensive experience in the diagnostic business and previously worked for Ortho Diagnostic Systems, Inc. and Pharmacia, where she helped develop diagnostic tools for pregnancy, HIV, Hepatitis B, and blood banking reagents.